Parabilis Medicines, Inc. (PBLS) Valuation | Quantisight AI

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-183.2%

-$22.66

vs $27.25 price

Levered DCF

-$15.32

After debt service

Piotroski score

—

Altman Z-score

—

Rating

C+

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024
P/E	-0.22×	-0.24×
P/B	-2.45×	0.69×
P/S	0×	0×
EV / EBITDA	-0.5×	-0.5×
Gross margin	0.0%	0.0%
Operating margin	0.0%	0.0%
Net margin	0.0%	0.0%
Current ratio	0.52×	2.84×
Debt / equity	-3.55×	1.17×
Interest coverage	-99.92×	-84.88×
Dividend yield	0.0%	0.0%
Payout ratio	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024
Return on equity	882.9%	-208.9%
Return on invested capital	-338.6%	-99.9%
Return on assets	-180.5%	-79.0%
Free cash flow yield	-306.5%	-270.1%
Earnings yield	-360.5%	-304.8%
Enterprise value	$71.5M	$57.6M
Net debt / EBITDA	-0.22×	-0.17×
Cash conversion cycle (days)	0	0